Anti-cancer oligodeoxynucleotides

Details Anti-cancer oligodeoxynucleotides Anti-cancer oligodeoxynucleotides

2009-12-03

2011-11-08

Vivlemore, Tracy (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500

Reexamination Certificate

active

08053422

ABSTRACT:
It is disclosed herein that suppressive ODNs are of use for preventing or delaying the formation of a tumor, reducing the risk of developing a tumor, treating a tumor, preventing conversion of a benign to a malignant lesion, or preventing metastasis. In some embodiments, methods are disclosed herein for treating, preventing or reducing the risk of developing a tumor, such as esophageal, gastrointestinal, liver, lung, skin and colon tumors or a mesothelioma. Generally, the methods disclosed herein include selecting a subject for treatment and administering to the subject a therapeutically effective amount of one or more suppressive ODN. In some examples, additional agents can also be administered to the subject of interest.

REFERENCES:
patent: 6653292 (2003-11-01), Krieg et al.
patent: 7087586 (2006-08-01), Filion et al.
patent: 7119078 (2006-10-01), Jing et al.
patent: 7358068 (2008-04-01), Vaillant et al.
patent: 2004/0132682 (2004-07-01), Klinman et al.
patent: 2004/0248834 (2004-12-01), Klinman et al.
patent: 2005/0239733 (2005-10-01), Jurk et al.
patent: WO 03/027313 (2003-04-01), None
patent: WO 2006/135434 (2006-12-01), None
Klinman et al., “Therapeutic potential of oligonucleotides expressing immunosuppressive TTAGGG motifs,”Ann NY Acad Sci1058:87-95, 2005.
Klinman et al., Lecture entitled “Synthetic oligonucleotides as modulations of inflammation,” National Cancer Institute sponsored Symposium, Apr. 10-11, 2008;J. Leuk. Biol. 84:1-7 (uncorrected version released on-line Apr. 22, 2008).
Klinman, “Immunotherapeutic uses of CpG oligodeoxynucleotides,”Nat. Rev. Immun., 4:249-258, 2004.
Krieg, “Development of TLR9 agonists for cancer therapy,”J. Clin. Invest. 117(5):1184-1194, 2007.
Merrell et al., “Toll-Like Receptor 9 Agonists Promote Cellular Invasion by Increasing Matrix Metalloproteinase Activity,”Molec. Cancer Res. 10:1541-7786, 2006.
Peter et al., “Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity,”Immunology123:118-128, 2007.
Riou et al., “Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands,”Proc. Natl. Acad. Sci. 99:2672-2677, 2002.
Sato et al., “Suppressive oligodeoxynucleotides inhibit silica-induced pulmonary inflammation,”J. Immunol. 180(11):7648-7654, 2008.
Shirota et al., “Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma- and IL-12-mediated signaling,”J. Immunol. 173(8):5002-5007, 2004.
Shirota et al., “Suppressive Oligodeoxynucleotides Protect Mice from Lethal Endotoxic Shock,”J. Immunol. 174:4579-4583, 2005.
Yamada et al., “Effect of Suppressive DNA on CpG-Induced Immune Activation,”J. Immunol. 169:5590-5594, 2002.
Yamada et al., “Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung,”Crit. Care Med. 32(10):2045-2049, 2004.

Affiliated with

Also associated with

Rating

Anti-cancer oligodeoxynucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cancer oligodeoxynucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer oligodeoxynucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4298777